← board
RMTI
distress 0/10 · well-funded / low risk$6.410%today-65% from 52w high
Revenue
pre-revenue
Liquidity
$10M
Runway
—
Shares 1y
+15%
Price & events
-42.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
+11.9%
1W
-4.3%
1M
-25.5%
3M
-44.3%
6M
-42.8%
1Y
-67.0%
2Y
-92.2%
5Y
-94.3%
All
Overview
- Market Cap
- $253.00M
- Enterprise Value
- $251.60M
- Volume
- 722
- 52 Week Range
- $5.19 – $18.30
- Total Shares
- 39.47M
- Float Shares
- 3.51M
- Short %
- 2.08%
- % Held by Insiders
- 15.12%
- % Held by Institutions
- 10.08%
- RVOL
- 0.02x
- Beta
- 1.61
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-08-13earningsEarningsEarnings releaseyahoo
- 2025-12-31partnershipExtended supply agreement with DaVita to Dec 31, 2026 with price increaseSEC 8-K
Approved drugs (3)
- TRIFERIC AVNUFERRIC PYROPHOSPHATE CITRATE2020 · Discontinued
- TRIFERICFERRIC PYROPHOSPHATE CITRATE2016 · Discontinued
- TRIFERICFERRIC PYROPHOSPHATE CITRATE2015 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $30 (+368% upside) · 2 analysts
- 2026-07-09HC Wainwright & Co.Buy
- 2026-03-30HC Wainwright & Co.Buy
- 2026-01-26HC Wainwright & Co.Buy
- 2025-11-13HC Wainwright & Co.Buy
- 2025-03-24HC Wainwright & Co.Buy
- 2024-12-23HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- 2026-07-23Rockwell Medical names Brian Cox VP, quality and regulatory compliance - Medical Buyer
- 2026-07-22Rockwell Medical names Brian Cox quality compliance chief By Investing.com - Investing.com Nigeria
- 2026-07-22Rockwell Medical Advances Quality and Regulatory Leadership - The Joplin Globe
- 2026-07-22Rockwell Medical Advances Quality and Regulatory Leadership - Eagle-Tribune
- 2026-07-22MI-ROCKWELL-MEDICAL - Black Hills Pioneer
- 2026-07-22Rockwell Medical Advances Quality and Regulatory Leadership - Voice of Alexandria
- 2026-07-21Rockwell Medical regains compliance with Nasdaq listing norms - Medical Buyer
- 2026-07-20Rockwell Medical Regains Compliance With Nasdaq Minimum Bid Price Requirement - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.